Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced .

In fact, some of the participants dropped out of the trial because they were losing too much weight, the pharmaceutical company said.

Retatrutide is an experimental triple agonist medication, mimicking three different gut hormones in the body — GLP-1, GIP and glucagon — whereas Eli Lilly's widely popular Zepbound and Mounjaro medications, made with tirzepatide, address only two of those hormones.

RELATED STORY | Eli Lilly could bring first widely available GLP‑1 pill for obesity, diabetes to market this year

Other medications, such as Novo Nordisk's Wegovy and Ozempic drugs, are made

See Full Page